Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (15,756,665)	$ (7,845,867)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	876,756	295,684
Amortization of right of use assets	237,868	197,339
Depreciation	2,925	791
Forgiveness of PPP loan	(37,772)
Non-cash interest on redeemable preferred stock	108,591
Current milestone payable to Patagonia Pharmaceuticals, LLC	1,750,000
Changes in assets and liabilities:
Prepaid research and development	(655,904)
Other current assets	(52,017)	39,090
Deposits		(13,000)
Accounts payable	120	647,241
Accrued expenses	1,109,506	(108,796)
Lease liability	(244,287)	(186,236)
Net cash used in operating activities	(12,660,879)	(6,973,754)
Cash flows from investing activities
Purchase of property and equipment	(5,947)	(17,803)
Net cash used in investing activities	(5,947)	(17,803)
Cash flows from financing activities
Proceeds from the issuance of common stock and warrants, net of issuance costs of $1,061,520	6,938,484
Proceeds from the exercise of common stock warrants	144,000
Net cash provided by financing activities	7,082,484
Net decrease in cash	(5,584,342)	(6,991,557)
Cash, beginning of period	16,808,539	10,348,693
Cash, end of period	11,224,197	3,357,136
Non-cash investing and financing activities:
Conversion of Redeemable Series A convertible preferred stock to prefunded common stock warrants	2,163,937
Current milestone payable to Patagonia Pharmaceuticals LLC	1,750,000
Accrued Series A preferred stock dividend		108,858
Cashless exercise of VARs	$ 60
Series A Warrants
Non-cash investing and financing activities:
Cashless exercise of warrants		2,060
Series B Warrants
Non-cash investing and financing activities:
Cashless exercise of warrants		$ 7,468